📊 PDSB Key Takeaways
Is PDS Biotechnology Corp (PDSB) a Good Investment?
PDS Biotech is a pre-revenue or severely revenue-constrained pharmaceutical company with persistent operating losses (-6.5M), negative cash flow (-4.4M), and dangerous leverage (5.14x debt-to-equity). Despite modest YoY loss improvement, the company lacks revenue generation capacity and cannot service its 20M debt burden from operations, creating acute solvency risk despite adequate near-term cash reserves.
PDS Biotechnology Corp Key Strengths (PDSB)
- Cash position of 21.7M provides 12-18 month operational runway
- Profitability trend improving (net income loss down 8.3% YoY; EPS loss down 28.2% YoY)
- Strong current liquidity ratio of 2.26x suggests no immediate short-term default risk
PDSB Stock Risks: PDS Biotechnology Corp Investment Risks
- Zero or immaterial revenue indicates failed commercialization or early pre-revenue stage with execution risk
- Chronic negative operating cash flow (-4.4M) with no offsetting revenue stream unsustainable beyond 5 years
- Extreme leverage (5.14x debt-to-equity; 20M debt on 3.9M equity) with negative interest coverage (-1.4x) signals distress refinancing needed within 12-24 months
- ROE of -188.8% and ROA of -29.8% indicate severe shareholder value destruction
- High Form 4 insider activity (11 filings/90 days) may signal insider concern or equity dilution
Key Metrics to Watch
- Revenue generation timeline and Q-over-Q revenue growth rate
- Operating cash burn rate and remaining cash runway months
- Debt refinancing activity and covenant compliance status
- Pipeline advancement milestones (FDA approvals, trial progression)
PDS Biotechnology Corp (PDSB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.26x current ratio provides a solid financial cushion.
PDSB Profit Margin, ROE & Profitability Analysis
PDSB vs Healthcare Sector: How PDS Biotechnology Corp Compares
How PDS Biotechnology Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PDS Biotechnology Corp Stock Overvalued? PDSB Valuation Analysis 2026
Based on fundamental analysis, PDS Biotechnology Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PDS Biotechnology Corp Balance Sheet: PDSB Debt, Cash & Liquidity
PDSB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PDS Biotechnology Corp's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.03 indicates the company is currently unprofitable.
PDSB Revenue Growth, EPS Growth & YoY Performance
PDS Biotechnology Corp Dividends, Buybacks & Capital Allocation
PDSB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PDS Biotechnology Corp (CIK: 0001472091)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PDSB
What is the AI rating for PDSB?
PDS Biotechnology Corp (PDSB) has an AI grade of D with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PDSB's key strengths?
Claude: Cash position of 21.7M provides 12-18 month operational runway. Profitability trend improving (net income loss down 8.3% YoY; EPS loss down 28.2% YoY).
What are the risks of investing in PDSB?
Claude: Zero or immaterial revenue indicates failed commercialization or early pre-revenue stage with execution risk. Chronic negative operating cash flow (-4.4M) with no offsetting revenue stream unsustainable beyond 5 years.
What is PDSB's revenue and growth?
PDS Biotechnology Corp reported revenue of N/A.
Does PDSB pay dividends?
PDS Biotechnology Corp does not currently pay dividends.
Where can I find PDSB SEC filings?
Official SEC filings for PDS Biotechnology Corp (CIK: 0001472091) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PDSB's EPS?
PDS Biotechnology Corp has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PDSB's fundamental grade?
Based on our AI fundamental analysis in June 2026, PDS Biotechnology Corp has a D grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PDSB stock overvalued or undervalued?
Valuation metrics for PDSB: ROE of -188.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PDSB's AI grade for 2026?
Our dual AI analysis gives PDS Biotechnology Corp a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PDSB's free cash flow?
PDS Biotechnology Corp's operating cash flow is $-4.4M, with capital expenditures of $0.0.
How does PDSB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -188.8% (avg: 15%), current ratio 2.26 (avg: 2).
Is PDS Biotechnology Corp carrying too much debt?
PDSB has a debt-to-equity ratio of 5.14x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.26 suggests adequate short-term liquidity.